Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Anaveon appoints Dieter Weinand as Chair of its Board of Directors BASEL, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dieter Weinand, former Chair and CEO of Bayer...

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study